WallStSmart

Healthpeak Properties Inc (DOC)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 9% more annual revenue ($3.07B vs $2.82B). WST leads profitability with a 16.1% profit margin vs 2.5%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 55/100 (C-).

DOC

Buy

54

out of 100

Grade: C-

Growth: 7.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.24

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOCSignificantly Overvalued (-262.4%)

Margin of Safety

-262.4%

Fair Value

$4.68

Current Price

$16.70

$12.02 premium

UndervaluedFair: $4.68Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$245.27

$176.28 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DOC4 strengths · Avg: 9.0/10
Return on EquityProfitability
116.0%10/10

Every $100 of equity generates 116 in profit

EPS GrowthGrowth
2448.0%10/10

Earnings expanding 2448.0% YoY

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

DOC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.1%4/10

3.1% revenue growth

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Debt/EquityHealth
1.393/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : DOC

The strongest argument for DOC centers on Return on Equity, EPS Growth, Price/Book.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : DOC

The primary concerns for DOC are Revenue Growth, Profit Margin, Debt/Equity. A P/E of 170.5x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

DOC profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

DOC generates stronger free cash flow (242M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 54/100), backed by strong 16.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthpeak Properties Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are rented to physicians, hospitals and healthcare delivery systems.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?